Evidence map›Paper›PMID 30850872›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2019

Akira Toriihara, Heying Duan, Holly M Thompson, Sonya Park, Negin Hatami, Lucia Baratto, Alice C Fan, Andrei Iagaru

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01806675 (Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01806675 phase1 / phase2completednot on this map

Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis

TypeinterventionalSponsorSanjiv Sam GambhirRan2013 to 2019Enrolled25ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast CancerArms18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Head-to-head evaluation of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  2. Comparative study of [Theranostics · 2025
    Article
  3. EGFR- and Integrin αInternational journal of molecular sciences · 2024
    Review
  4. Review
  5. [European journal of nuclear medicine and molecular imaging · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Akira ToriiharaDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Heying DuanDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Holly M ThompsonDepartment of Nuclear Medicine, Kaiser Permanente, Santa Clara, CA, USA.
Sonya ParkDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Negin HatamiDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Lucia BarattoDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Alice C FanDivision of Oncology, Department of Medicine, Stanford University, 269 Campus Drive, Stanford, CA, 94305, USA. afan@stanford.edu.
Andrei IagaruDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA. aiagaru@stanford.edu.ORCID http://orcid.org/0000-0003-0839-5329

Funding

Alpern Foundation N/AAmerican Society of Clinical Oncology N/A
6 · The paper itself

Abstract

purposeThe usefulness of positron emission tomography/computed tomography (PET/CT) using (

methodsSeven patients with mRCC were enrolled in this prospective study.

resultsSixty lesions in total were detected in this cohort. SUV

conclusions

Indexed as

Positron Emission Tomography Computed TomographyAgedAged, 80 and overAngiogenesis InhibitorsCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleMiddle AgedNeoplasm MetastasisPeptides, CyclicPilot ProjectsProspective StudiesAngiogenesis InhibitorsFPP(RGD)2Peptides, Cyclic18F-FDG18F-FPPRGD2Antiangiogenic therapyPET/CTRenal cell cancer

Identifiers

PMID30850872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.